Skip to main content
Top
Literature
1.
go back to reference Casanova J, Bonagura V. J Clin Immunol. 2018;38(4):445–6. Casanova J, Bonagura V. J Clin Immunol. 2018;38(4):445–6.
2.
go back to reference Picard C, Gaspar BH, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.CrossRef Picard C, Gaspar BH, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.CrossRef
3.
go back to reference Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRef Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRef
4.
go back to reference Queiroz-Telles F, Mercier T, Maertens J, Sola CBS, Bonfim C, Lortholary O, et al. Successful allogenic stem cell transplantation in patients with inherited CARD9 deficiency. J Clin Immunol. 2019;39(5):462–9.CrossRef Queiroz-Telles F, Mercier T, Maertens J, Sola CBS, Bonfim C, Lortholary O, et al. Successful allogenic stem cell transplantation in patients with inherited CARD9 deficiency. J Clin Immunol. 2019;39(5):462–9.CrossRef
5.
go back to reference Shouval DS, Kowalik M, Snapper SB. The treatment of inflammatory bowel disease in patients with selected primary immunodeficiencies. J Clin Immunol. 2018;38(5):579–88.CrossRef Shouval DS, Kowalik M, Snapper SB. The treatment of inflammatory bowel disease in patients with selected primary immunodeficiencies. J Clin Immunol. 2018;38(5):579–88.CrossRef
6.
go back to reference Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37(4):351–6.CrossRef Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37(4):351–6.CrossRef
7.
go back to reference Georgiev P, Charbonnier L-M, Chatila TA. Regulatory T cells: the many faces of Foxp3. J Clin Immunol. 2019;39(7):623–40.CrossRef Georgiev P, Charbonnier L-M, Chatila TA. Regulatory T cells: the many faces of Foxp3. J Clin Immunol. 2019;39(7):623–40.CrossRef
8.
go back to reference Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.CrossRef Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.CrossRef
9.
go back to reference Pöyhönen L, Bustamante J, Casanova J-L, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRef Pöyhönen L, Bustamante J, Casanova J-L, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRef
10.
go back to reference Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019;39(3):277–86.CrossRef Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019;39(3):277–86.CrossRef
11.
go back to reference Tangye SG, Bier J, Lau A, Nguyen T, Uzel G, Deenick EK. Immune dysregulation and disease pathogenesis due to activating mutations in PIK3CD—the Goldilocks’ effect. J Clin Immunol. 2019;39(2):148–58.CrossRef Tangye SG, Bier J, Lau A, Nguyen T, Uzel G, Deenick EK. Immune dysregulation and disease pathogenesis due to activating mutations in PIK3CD—the Goldilocks’ effect. J Clin Immunol. 2019;39(2):148–58.CrossRef
12.
go back to reference Delmonte OM, Schuetz C, Notarangelo LD. RAG deficiency: two genes, many diseases. J Clin Immunol. 2018;38(6):646–55.CrossRef Delmonte OM, Schuetz C, Notarangelo LD. RAG deficiency: two genes, many diseases. J Clin Immunol. 2018;38(6):646–55.CrossRef
13.
go back to reference Corvilain E, Casanova J-L, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. J Clin Immunol. 2018;38(6):656–93.CrossRef Corvilain E, Casanova J-L, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. J Clin Immunol. 2018;38(6):656–93.CrossRef
14.
go back to reference Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558–68.CrossRef Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558–68.CrossRef
15.
go back to reference Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–78.CrossRef Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–78.CrossRef
16.
go back to reference Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. J Clin Immunol. 2018;38(1):13–27.CrossRef Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. J Clin Immunol. 2018;38(1):13–27.CrossRef
17.
go back to reference Gallo V, Cirillo E, Giardino G, Pignata C. FOXN1 deficiency: from the discovery to novel therapeutic approaches. J Clin Immunol. 2017;37(8):751–8.CrossRef Gallo V, Cirillo E, Giardino G, Pignata C. FOXN1 deficiency: from the discovery to novel therapeutic approaches. J Clin Immunol. 2017;37(8):751–8.CrossRef
18.
go back to reference Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626–37.CrossRef Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626–37.CrossRef
19.
go back to reference Boisson B, Puel A, Picard C, Casanova J-L. Human IκBα gain of function: a severe and syndromic immunodeficiency. J Clin Immunol. 2017;37(5):397–412.CrossRef Boisson B, Puel A, Picard C, Casanova J-L. Human IκBα gain of function: a severe and syndromic immunodeficiency. J Clin Immunol. 2017;37(5):397–412.CrossRef
20.
go back to reference Klein C. Kostmann’s disease and HCLS1-associated protein X-1 (HAX1). J Clin Immunol. 2017;37(2):117–22.CrossRef Klein C. Kostmann’s disease and HCLS1-associated protein X-1 (HAX1). J Clin Immunol. 2017;37(2):117–22.CrossRef
21.
go back to reference Meyts I. Hematopoietic stem cell transplantation in CARD9 deficiency: knight in shining armor? J Clin Immunol. 2019;39(5):459–61.CrossRef Meyts I. Hematopoietic stem cell transplantation in CARD9 deficiency: knight in shining armor? J Clin Immunol. 2019;39(5):459–61.CrossRef
22.
go back to reference Bonagura VR. Successful rituximab treatment for lymphoma, secondary immunodeficiency causing debilitating sinusitis: underlying primary immunodeficiency disease, and alternative treatments to improve the quality of life? J Clin Immunol. 2019;39(3):229–30.CrossRef Bonagura VR. Successful rituximab treatment for lymphoma, secondary immunodeficiency causing debilitating sinusitis: underlying primary immunodeficiency disease, and alternative treatments to improve the quality of life? J Clin Immunol. 2019;39(3):229–30.CrossRef
23.
go back to reference Aiuti A, Quinti I. In Memoriam: Fernando Aiuti, MD (June 8, 1935–January 9, 2019). J Clin Immunol. 2019;39(2):142–3.CrossRef Aiuti A, Quinti I. In Memoriam: Fernando Aiuti, MD (June 8, 1935–January 9, 2019). J Clin Immunol. 2019;39(2):142–3.CrossRef
24.
go back to reference Lankester A, Heidt P, Rümke H, Bredius R, van Tol M. In Memoriam: Prof. Dr. J.M.J.J. Vossen (1937-2019). J Clin Immunol. 2019;39(6):530–1.CrossRef Lankester A, Heidt P, Rümke H, Bredius R, van Tol M. In Memoriam: Prof. Dr. J.M.J.J. Vossen (1937-2019). J Clin Immunol. 2019;39(6):530–1.CrossRef
25.
go back to reference Condino-Neto A. Prof. Dr. Beatriz Tavares Costa-Carvalho Obituary. J Clin Immunol. 2019;39(6):529.CrossRef Condino-Neto A. Prof. Dr. Beatriz Tavares Costa-Carvalho Obituary. J Clin Immunol. 2019;39(6):529.CrossRef
26.
go back to reference Crow YJ, Lebon P, Casanova J-L, Gresser I. A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo. J Clin Immunol. 2018;38(6):694–8.CrossRef Crow YJ, Lebon P, Casanova J-L, Gresser I. A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo. J Clin Immunol. 2018;38(6):694–8.CrossRef
Metadata
Title
Editorial, Journal of Clinical Immunology
Authors
Jean-Laurent Casanova
Vincent Bonagura
Publication date
01-11-2019
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 8/2019
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00699-0

Other articles of this Issue 8/2019

Journal of Clinical Immunology 8/2019 Go to the issue